alan p. venook, md, explains how the 80405 study and its impact on treatment guidelines
Published 7 years ago • 26 plays • Length 1:41
Download video MP4
Download video MP3
Similar videos
-
1:38
alan venook, md explains the outcome of phase 3 calgb/swog 80405 study
-
0:55
dr. venook discusses implications of the calgb/swog 80405 study
-
1:19
alan venook, md on whether calgb/swog 80405 study provides guidance on therapeutic regimen
-
1:44
alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms
-
1:54
alan venook, md, explains how tumor sidedness affects therapeutic choice
-
1:07
dr. venook discusses the results of the 80405 trial
-
8:41
calgb 80405 trial results in metastatic colorectal cancer
-
1:39
alan venook, md, discusses next generation sequencing and mcrc treatment
-
1:05
alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients
-
1:01
alan venook, md talks about treatment strategies based on site of primary tumor in crc patients
-
1:30
alan venook, md, discusses vemurafenib and the nccn guidelines for mcrc patients
-
1:54
alan p. venook, md, on integrating immunotherapy into existing treatment regimens for hcc patients
-
2:03
alan venook, md, explains the biological difference between left-sided and right-sided crc tumors
-
1:37
alan p. venook, md, on integrating immunotherapy into existing treatment regimens for crc patients
-
2:12
alan venook, md, considers how i-o is evolving towards the first line treatment of colorectal cancer
-
1:26
dr. alan venook on geographic variations in the therapies used to treat cancer
-
2:16
alan venook, md, describes the potential practice changing results of the keynote-177 study
-
1:42
dr. alan p. venook on determining frontline treatment for mcrc
-
1:21
alan p. venook, md, provides his perspective on using tas-102 and regorafenib in crc patients
Clip.africa.com - Privacy-policy